Acumen Hypotension Prediction Index – EV1000 Clinical Platform vs Cleerly LABS

Tool A, Acumen HPI, is designed for real-time, continuous monitoring in acute care settings, providing immediate alerts and insights at the patient's bedside. Its integration with existing monitoring platforms and continuous parameter updates every 20 seconds make it highly actionable in critical situations. Tool B, Cleerly LABS, offers a web-based platform for diagnostic review, which is usable for its purpose but less immediate in its interaction model.

Both tools offer significant clinical value, but Acumen HPI directly addresses acute, life-threatening events by predicting hypotension up to 15 minutes in advance and providing insights into its root causes. Multiple randomized controlled trials have demonstrated its effectiveness in significantly reducing the incidence, duration, and severity of intraoperative hypotension. While Cleerly LABS provides comprehensive insights for chronic disease management, the immediate, predictive, and potentially life-saving intervention capability of Tool A in an acute setting gives it a slight edge in direct clinical impact.

Tool B, Cleerly LABS, offers transparent pricing, detailing its per-analysis cost, potential discounts, and the separate cost of the CCTA scan, along with information on insurance coverage and specific CPT codes for billing. In contrast, Tool A's pricing is opaque, requiring direct contact with the company, and available information suggests a substantial upfront hardware investment without clear evidence of cost savings. Therefore, Tool B provides better clarity and transparency regarding its cost and potential value.

Both tools are FDA cleared and HIPAA compliant, establishing a foundational level of enterprise readiness. However, Tool B, Cleerly LABS, demonstrates superior enterprise readiness through its cloud-native architecture on AWS, explicit integration capabilities with PACS, RIS, and EHR via a proxy and API, and a focus on scalability, redundancy, and disaster recovery. Tool A's integration with a specific hardware platform may present more limited deployment flexibility for diverse enterprise environments.

Both tools are highly innovative. Acumen HPI's real-time, machine learning-driven prediction of acute hypotensive events with actionable insights is groundbreaking for critical care. However, Cleerly LABS offers a broader and potentially more transformative innovative vision by providing comprehensive, AI-driven quantitative and qualitative assessment of coronary plaque from CCTA, aiming to redefine the standard of care for heart disease prevention and potentially 'eliminate heart attacks.' Its ability to track disease progression and integrate atherosclerosis, stenosis, and ischemia assessment from a single non-invasive test represents a significant leap in chronic disease management.

Tool A, Acumen HPI, explicitly offers 24/7 technical support, which is a critical advantage for a device used in acute, real-time patient monitoring settings. While Tool B, Cleerly LABS, provides support during business hours with priority for after-hours needs, it does not explicitly guarantee 24/7 availability. The continuous nature of critical care necessitates round-the-clock support.